Answer
Kesimpta (ofatumumab) is contraindicated in patients with hypersensitivity to ofatumumab or any excipient, a severely immunocompromised state, severe active infection until resolution, or known active malignancy.
Sources for this answer
- Kesimpta 20 mg solution for injection in pre-filled penNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.3 Contraindications · Version 9Document updated
Sources checked